← All trials
NCT05495893
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2022
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Aug 10, 2022
- Last posted
- Aug 10, 2022
- Enrollment
- 224
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Central South UniversityLead sponsor
- Capital Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Jiangxi Children's HospitalCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Central South UniversityReponsible party - principal investigator
- Central South UniversityStudy chair
- Shenzhen UniversityCollaborator
- Qingdao UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Central South UniversitySponsor investigator
- Central South UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.